Suzuken reported better-than-expected Q1FY24 result, driven by specialty drug contracts and COVID-19 products. However, the company expects decline in revenue, op. profit, and net profit in FY24.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.